As part of the Phase III trial of a vaccine developed by Oxford University and British pharmaceutical company AstraZeneca in July 2020, a Brazilian doctor voluntarily accepted the injection.
Nelson Almeida | AFP | Getty Images
LONDON — The coronavirus vaccine developed by Oxford University and AstraZeneca has been approved for emergency use in the UK, marking another step in the global fight against the pandemic.
According to government statistics, the vaccine is expected to be launched next week and will be added to Pfizer-BioNTech vaccine. To date, the vaccine has been provided to 600,000 people in the UK.
AstraZeneca said in a statement that the first dose of the vaccine will be released on Wednesday, “in order to start vaccination early in the new year.”
It added that it “intended to provide millions of doses in the first quarter” as part of its agreement with the British government to provide up to 100 million doses in total.
British Government Secretary Michael Gove said on Monday that the approval of the Oxford-AstraZeneca vaccine may accelerate the lifting of the country’s strict confinement, which effectively cancels millions of Christmas celebrations.
There is a surge in cases in London and southern England, and hospitals are under tremendous pressure. According to reports, a new variant of the coronavirus discovered in the UK spreads more easily and causes travel restrictions for people who want to leave the country.
The Oxford-AstraZeneca vaccine has allowed the UK to greatly improve its vaccination schedule. It is also cheaper than others and does not need to be kept at ultra-low temperatures.
AstraZeneca CEO Pascal Soriot said in a statement: “Today is an important day for millions of people in the UK who are willing to use this new vaccine. It turns out that this vaccine It is effective, well tolerated, easy to manage and easy to use. Provided by AstraZeneca without any profit.”
AstraZeneca’s vaccine is a viral vector vaccine based on a weakened version of the common cold virus that causes chimpanzee infection. If it later infects the human body, it aims to stimulate the immune system to attack the coronavirus, namely SARS-CoV-2.
Dr. Richard Horton, editor-in-chief of the medical journal The Lancet, told CNBC in December that these advantages mean it can be used more effectively on a global scale.
Horton said: “The Oxford AstraZeneca vaccine is currently more effective than any other vaccines we have and can immunize the planet more quickly.” He added that it is very important to consider vaccine immunization on a global scale. “Because Even if we immunize one country, the threat is that you reintroduced the virus from another unprotected country.”
Confusion over its test data in November led to some criticism of AstraZeneca. Preliminary figures indicate that the vaccine can help reduce the spread of Covid-19 and prevent disease and death. The study also found that the trial participants who received two full doses had 62% effectiveness, but the subgroup that gave half the dose and then the full dose had 90% effectiveness.
The White House Operations Director Moncef Slaoui and others in the United States expressed concern about the age group tested, saying that 90% of the efficacy was only for the lowest risk group, which showed 2741 people under 55 years of age.
— CNBC Sam Meredith Contributed to this article.